Paulo Victor Sgobbi Souza

Dr. Paulo Victor Sgobbi Souza

Assistant Neurologist, Division of Neuromuscular Diseases, Neurometabolic Unit, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
PNPaulo Ribeiro Nóbrega
Paulo Ribeiro Nóbrega
ABAnderson Moura Bernardes
Anderson Moura Bernardes
RRRodrigo Mariano Ribeiro
Rodrigo Mariano Ribeiro
SVSophia Costa Vasconcelos
Sophia Costa Vasconcelos
DADavid Augusto Batista Sá Araújo
David Augusto Batista Sá Araújo
PBPedro Braga-Neto
Pedro Braga-Neto
Cerebrotendinous Xanthomatosis represents a rare and underdiagnosed inherited neurometabolic disorder due to homozygous or compound heterozygous variants involving the CYP27A1 gene. This bile acid metabolism disorder represents a key potentially treatable neurogenetic condition due to the wide spectrum of neurological presentations in which it most commonly occurs. Cerebellar ataxia, peripheral neuropathy, spastic paraparesis, epilepsy, parkinsonism, cognitive decline, intellectual disability, and neuropsychiatric disturbances represent some of the most common neurological signs observed in this condition. Despite representing key features to increase diagnostic index suspicion, multisystemic involvement does not represent an obligatory feature and can also be under evaluated during diagnostic work-up. Chenodeoxycholic acid represents a well-known successful therapy for this inherited metabolic disease, however its unavailability in several contexts, high costs and common use in patients at late stages of disease course limit more favorable neurological outcomes for most individuals. This review article aims to discuss and highlight the most recent and updated knowledge regarding clinical, pathophysiological, neuroimaging, genetic and therapeutic aspects related to Cerebrotendinous Xanthomatosis.

14 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
ARAuro Ricarte
Auro Ricarte
BBBruno de Mattos Lombardi Badia
Bruno de Mattos Lombardi Badia
DSDaniel Delgado Seneor
Daniel Delgado Seneor
AOAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira

27 July 2022 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
MSMarianela Schiava
Marianela Schiava
CIChiseko Ikenaga
Chiseko Ikenaga
RVRocío Nur Villar-Quiles
Rocío Nur Villar-Quiles
MCMarta Caballero-Ávila
Marta Caballero-Ávila
ATAna Topf
Ana Topf
JDJordi Díaz-Manera
Jordi Díaz-Manera
Background: Valosin-containing protein (VCP) disease, caused by mutations in the VCP gene, results in myopathy, Paget’s disease of bone (PBD) and frontotemporal dementia (FTD). Natural history and genotype–phenotype correlation data are limited. This study characterises patients with mutations in VCP gene and investigates genotype–phenotype correlations.Methods: Descriptive retrospective international study collecting clinical and genetic data of patients with mutations in the VCP gene.Results: Two hundred and fifty-five patients (70.0% males) were included in the study. Mean age was 56.8±9.6 years and mean age of onset 45.6±9.3 years. Mean diagnostic delay was 7.7±6 years. Symmetric lower limb weakness was reported in 50% at onset progressing to generalised muscle weakness. Other common symptoms were ventilatory insufficiency 40.3%, PDB 28.2%, dysautonomia 21.4% and FTD 14.3%. Fifty-seven genetic variants were identified, 18 of these no previously reported. c.464G>A (p.Arg155His) was the most frequent variant, identified in the 28%. Full time wheelchair users accounted for 19.1% with a median time from disease onset to been wheelchair user of 8.5 years. Variant c.463C>T (p.Arg155Cys) showed an earlier onset (37.8±7.6 year) and a higher frequency of axial and upper limb weakness, scapular winging and cognitive impairment. Forced vital capacity (FVC) below 50% was as risk factor for being full-time wheelchair user, while FVC <70% and being a full-time wheelchair user were associated with death.Conclusion: This study expands the knowledge on the phenotypic presentation, natural history, genotype–phenotype correlations and risk factors for disease progression of VCP disease and is useful to improve the care provided to patient with this complex disease.

3 November 2020 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
BBBruno Mattos Lombardi Badia
Bruno Mattos Lombardi Badia
IFIgor Braga Farias
Igor Braga Farias
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
AOAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
SDSalvatore DiMauro
Salvatore DiMauro

1 April 2019 in Revue Neurologique
Verified
Journal Article
Closed access
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
RDR. Debona
R. Debona
PNP.P. Nunes
P.P. Nunes
AAA.C.D. Assis
A.C.D. Assis
CLC.G. Lopes
C.G. Lopes
AOA.S.B. Oliveira
A.S.B. Oliveira

27 September 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
BBBruno de Mattos Lombardi Badia
Bruno de Mattos Lombardi Badia
IFIgor Braga Farias
Igor Braga Farias
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
AOAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Acute hepatic porphyria represents a rare, underdiagnosed group of inherited metabolic disorders due to hereditary defects of heme group biosynthesis pathway. Most patients have their definite diagnosis after several years of complex and disabling clinical manifestations and commonly after life-threatening acute neurovisceral episodes or severe motor handicap. Many key studies in the last two decades have been performed and led to the discovery of novel possible diagnostic and prognostic biomarkers and to the development of new therapeutic purposes, including small interfering RNA-based therapy, specifically driven to inhibit selectively delta-aminolevulinic acid synthase production and decrease the recurrence number of severe acute presentation for most patients. Several distinct mechanisms have been identified to contribute to the several neuromuscular signs and symptoms. This review article aims to present the current knowledge regarding the main pathophysiological mechanisms involved with the acute and chronic presentation of acute hepatic porphyria and to highlight the relevance of such content for clinical practice and in decision making about therapeutic options.